Valuation: Indivior PLC

Market Cap 6.17B 5.59B 5.17B 4.67B 8.8B 582B 9.11B 62.16B 24.65B 311B 23.17B 22.68B 987B P/E 2026 *
12.9x
P/E 2027 * 16x
Enterprise Value 6.17B 5.59B 5.17B 4.67B 8.8B 582B 9.11B 62.16B 24.65B 311B 23.17B 22.68B 987B EV / Sales 2026 *
2.73x
EV / Sales 2027 * 2.52x
Free-Float
97.94%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-1.64% - - 6.17B
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.06%+2.08%+35.39%+83.36% 477B
Weighted average by Cap. +0.53%+3.26%+37.70%+96.50%

Financials

2026 *2027 *
Net sales 2.26B 2.05B 1.9B 1.71B 3.23B 214B 3.34B 22.81B 9.04B 114B 8.5B 8.32B 362B 2.45B 2.22B 2.05B 1.85B 3.49B 231B 3.61B 24.65B 9.77B 123B 9.19B 8.99B 391B
Net income 496M 450M 416M 375M 707M 46.8B 732M 5B 1.98B 25B 1.86B 1.82B 79.35B 400M 362M 335M 302M 570M 37.69B 590M 4.03B 1.6B 20.14B 1.5B 1.47B 63.92B
Net Debt - -
Logo Indivior PLC
Supernus, Inc., formerly Indivior Pharmaceuticals, Inc., is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The Company's commercial platform offers various product portfolios consisting of opioid use disorder, psychiatry, and neurology, and includes five core growth drivers, including SUBLOCADE, Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE. Its portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Employees
833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Indivior PLC